ASCLETIS-B (01672) announced that on September 30, 2025, the company granted stock options to 10 participants (grantees) under the stock option scheme adopted by the company on February 3, 2025 (the 2025 Stock Option Scheme). The stock options entitle holders to subscribe for a total of 650,000 ordinary shares of the company, each with a par value of US$0.0001.